Lilly to Acquire Orna Therapeutics to Accelerate In Vivo CAR-T
TL;DR Summary
Eli Lilly will acquire Orna Therapeutics in a deal worth up to $2.4 billion in cash, expanding Lilly’s genetic-medicine platform with Orna’s circular-RNA–based in vivo CAR-T technology (ORN-252) designed to treat B cell–driven autoimmune diseases, leveraging lipid nanoparticle delivery for potentially more durable therapeutic protein expression and broader in vivo cell-therapy options.
- Lilly to acquire Orna Therapeutics to advance cell therapies PR Newswire
- Lilly bets on next-generation cell therapy with $2.4 billion deal for Orna Reuters
- Lilly Strikes Deal for Biotech Orna Worth Up to $2.4 Billion bloomberg.com
- Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena Fierce Biotech
- Eli Lilly makes $2.4B bet on RNA tech Axios
Reading Insights
Total Reads
1
Unique Readers
9
Time Saved
5 min
vs 6 min read
Condensed
95%
1,058 → 52 words
Want the full story? Read the original article
Read on PR Newswire